MFSD12 and cancer: We first performed univariate Cox regression analysis across 33 cancer types, which indicated that high MFSD12 expression was significantly associated with poorer overall survival (OS) in ACC (HR = 3.33, p = 4.09e−03), LAML (HR = 1.99, p = 1.73e−03), LGG (HR = 2.03, p = 1.33e−04), LIHC (HR = 1.62, p = 7.22e−03), LUAD (HR = 1.48, p = 8.61e−03), MESO (HR = 1.85, p = 1.04e−02), and OV (HR = 1.33, p = 2.92e−02), whereas it inversely correlated with favorable OS in ESCA (HR = 0.573, p = 2.69e−02), KIRP (HR = 0.548, p=5.50e−02), and UCBC (HR = 0.632, p=3.21e−02)(Figure 4A).